Skip to Main Content

Tri-TDI

News

March 2019

Small Molecule Discovered by TDI and Weill Cornell Medicine, Licensed to Bridge Medicine

October 2018

Ablexis, Inc. Licenses TDI-Generated Antibody

June 2018

Peter T. Meinke, PhD, Named New Sanders Director of the TDI

April 2018

TDI Renews Agreement with Schrödinger, Inc. for Access to Drug Discovery Software

March 2018

TDI Licenses First Project to Bridge Medicines

June 2017

TDI's Peter T. Meinke, PhD named "Hero of Chemistry"

May 2017

TDI teams with researchers at The Rockefeller University to develop novel dynein inhibitors

April 2017

Vincent Fischetti, PhD, TDI collaborator and professor at The Rockefeller University featured in Fierce Biotech

January 2017

Ablexis Announces Perpetual License of the AliaMab Mouse to the Tri-I TDI

September 2016

Discovering New Therapeutics through the Power of Philanthropy

June 2016

Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd.

October 2015

Weill Cornell profiles the Tri-I TDI in the October issue of <em>Weill Cornell Medicine</em>

August 2015

Cyclofluidic Announces Drug Discovery Agreement with the Tri-I TDI

February 2015

Horizon Discovery Group Selected as Core Facility by the Tri-Institutional Therapeutics Discovery Institute

October 2014

New agreement with Schrödinger a ‘game-changer’

September 2014

The Weill Cornell Medical College presents the MILSTEIN PROGRAM IN MEDICINAL CHEMISTRY SYMPOSIUM: FROM TARGET TO TREATMENT

December 2013

Accomplished Scientist and Entrepreneur Selected to Lead Tri-Institutional Therapeutics Discovery Institute

October 2013

Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership

October 2013

Tripling Up for Early-Stage Drug Development

October 2013

Tri-Institutional Therapeutics Discovery Institute, Inc. Launched by Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, and Partnership Formed with Takeda